Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
Sponsor: Priovant Therapeutics, Inc.
Summary
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement Score (TIS). After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52 week open-label extension phase where all participants will receive brepocitinib.
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
241
Start Date
2022-10-31
Completion Date
2026-07
Last Updated
2025-09-29
Healthy Volunteers
No
Conditions
Interventions
Brepocitinib
Oral Brepocitinib
Placebo
Oral Placebo
Locations (109)
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
Scottsdale, Arizona, United States
Clinical Trial Site
Scottsdale, Arizona, United States
Clinical Trial Site
Irvine, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
San Francisco, California, United States
Clinical Trial Site
Aurora, Colorado, United States
Clinical Trial Site
Denver, Colorado, United States
Clinical Trial Site
Boynton Beach, Florida, United States
Clinical Trial Site
Gainesville, Florida, United States
Clinical Trial Site
Jacksonville, Florida, United States
Clinical Trial Site
Plantation, Florida, United States
Clinical Trial Site
Tampa, Florida, United States
Clinical Trial Site
Atlanta, Georgia, United States
Clinical Trial Site
Augusta, Georgia, United States
Clinical Trial Site
Marietta, Georgia, United States
Clinical Trial Site
Chicago, Illinois, United States
Clinical Trial Site
Iowa City, Iowa, United States
Clinical Trial Site
Kansas City, Kansas, United States
Clinical Trial Site
New Orleans, Louisiana, United States
Clinical Trial Site
New Orleans, Louisiana, United States
Clinical Trial Site
Baltimore, Maryland, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Ann Arbor, Michigan, United States
Clinical Trial Site
Minneapolis, Minnesota, United States
Clinical Trial Site
Rochester, Minnesota, United States
Clinical Trial Site
Manhasset, New York, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
Cincinnati, Ohio, United States
Clinical Trial Site
Cleveland, Ohio, United States
Clinical Trial Site
Oklahoma City, Oklahoma, United States
Clinical Trial Site
Portland, Oregon, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Pittsburgh, Pennsylvania, United States
Clinical Trial Site
Jackson, Tennessee, United States
Clinical Trial Site
Austin, Texas, United States
Clinical Trial Site
Houston, Texas, United States
Clinical Trial Site
Irving, Texas, United States
Clinical Trial Site
Quilmes, Buenos Aires, Argentina
Clinical Trial Site
Caba, Buenos Aires F.D., Argentina
Clinical Trial Site
Mendoza, Argentina
Clinical Trial Site
Leuven, Belgium
Clinical Trial Site
Plovdiv, Bulgaria
Clinical Trial Site
Plovdiv, Bulgaria
Clinical Trial Site
Plovdiv, Bulgaria
Clinical Trial Site
Sofia, Bulgaria
Clinical Trial Site
Vancouver, British Colombia, Canada
Clinical Trial Site
Newmarket, Ontario, Canada
Clinical Trial Site
Concepción, Región del Biobío, Chile
Clinical Trial Site
Recoleta, Chile
Clinical Trial Site
Santiago, Chile
Clinical Trial Site
Santiago, Chile
Clinical Trial Site
Temuco, Chile
Clinical Trial Site
Prague, Czechia
Clinical Trial Site
Mainz, Rhineland-Palatinate, Germany
Clinical Trial Site
Berlin, Germany
Clinical Trial Site
Berlin, Germany
Clinical Trial Site
Dresden, Germany
Clinical Trial Site
Essen, Germany
Clinical Trial Site
Freiburg im Breisgau, Germany
Clinical Trial Site
Debrecen, Hungary
Clinical Trial Site
Pécs, Hungary
Clinical Trial Site
Szeged, Hungary
Clinical Trial Site
Ashkelon, Israel
Clinical Trial Site
Haifa, Israel
Clinical Trial Site
Poria – Neve Oved, Israel
Clinical Trial Site
Tel Aviv, Israel
Clinical Trial Site
Tel Litwinsky, Israel
Clinical Trial Site
Bari, Italy
Clinical Trial Site
Pavia, Italy
Clinical Trial Site
Roma, Italy
Clinical Trial Site
Torino, Italy
Clinical Trial Site
Monterrey, Nuevo León, Mexico
Clinical Trial Site
Mérida, Yucatán, Mexico
Clinical Trial Site
Guadalajara, Mexico
Clinical Trial Site
Mexico City, Mexico
Clinical Trial Site
San Luis Potosí City, Mexico
Clinical Trial Site
Nijmegen, Gelderland, Netherlands
Clinical Trial Site
Amsterdam, Netherlands
Clinical Trial Site
Bialystok, Podlaskie Voivodeship, Poland
Clinical Trial Site
Krakow, Poland
Clinical Trial Site
Lublin, Poland
Clinical Trial Site
Lublin, Poland
Clinical Trial Site
Nowa Sól, Poland
Clinical Trial Site
Poznan, Poland
Clinical Trial Site
Warsaw, Poland
Clinical Trial Site
Vila Nova de Gaia, Porto District, Portugal
Clinical Trial Site
Guimarães, Portugal
Clinical Trial Site
Lisbon, Portugal
Clinical Trial Site
Porto, Portugal
Clinical Trial Site
Bucharest, Romania
Clinical Trial Site
Cluj-Napoca, Romania
Clinical Trial Site
Belgrade, Serbia
Clinical Trial Site
Seoul, South Korea
Clinical Trial Site
Suwon, South Korea
Clinical Trial Site
Madrid, Spain
Clinical Trial Site
Kaohsiung City, Taiwan
Clinical Trial Site
Taichung, Taiwan
Clinical Trial Site
Tainan, Taiwan
Clinical Trial Site
Taipei, Taiwan
Clinical Trial Site
Ankara, Turkey (Türkiye)
Clinical Trial Site
Antalya, Turkey (Türkiye)
Clinical Trial Site
Istanbul, Turkey (Türkiye)
Clinical Trial Site
Izmir, Turkey (Türkiye)
Clinical Trial Site
İzmit, Turkey (Türkiye)
Clinical Trial Site
Bath, United Kingdom
Clinical Trial Site
Manchester, United Kingdom
Clinical Trial Site
Wolverhampton, United Kingdom